https://orcid.org/0000-0002-2815-4568
Figures & data
Table 1. Baseline comparison between hematologists who were capable and incapable of identifying the VTE risk factors.
Figure 1. Decision-making of thromboprophylaxis for various anti-MM regimens. VCd: bortezomib; cyclophosphamide, and dexamethasone; DVd: daratumumab, bortezomib, and dexamethasone; PAd: bortezomib, doxorubicin, and dexamethasone; VRd: bortezomib, lenalidomide, and dexamethasone; DRd: daratumumab, lenalidomide, and dexamethasone; VTD-PACE: bortezomib, thalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, and etoposide; KRd: carfilzomib, lenalidomide, and dexamethasone.
Table 2. Baseline comparison between hematologists who chose no thromboprophylaxis and chose thromboprophylaxis for VCd and DVd.
Figure 2. Thromboprophylaxis decisions for MM patients who have a disease relapse and receive the IMiDs-dexamethasone combined treatment.
Figure 3. Thromboprophylaxis decisions for MM patients who receive lenalidomide for maintenance therapy.
Figure 4. Medical decisions for MM patients who develop DVT/superficial venous thrombosis during the VRd treatment.
Figure 5. Decisions of whether or not to give IMiDs-based regimens to patients depicted in vignettes #4, #5, and #6.
Figure 6. Decision-making of thromboprophylaxis for six vignettes.
Table 3. Baseline comparison between hematologists in non-stratified thromboprophylaxis and stratified thromboprophylaxis groups.
Supplemental Material
Download Zip (17.4 KB)Data availability statement
The data used and/or analysed in the context of the current study are available from the corresponding author upon reasonable request.